Matsumoto, H.; Igarashi, C.; Tachibana, T.; Hihara, F.; Waki, A.; Zhang, M.-R.; Yoshida, S.; Naito, K.; Kurihara, H.; Ueno, M.;
et al. Characterization and Stabilization of a New 64Cu-Labeled Anti-EGFR Antibody NCAB001 for the Early Detection of Pancreatic Cancer with Positron Emission Tomography. Pharmaceutics 2022, 14, 67.
https://doi.org/10.3390/pharmaceutics14010067
AMA Style
Matsumoto H, Igarashi C, Tachibana T, Hihara F, Waki A, Zhang M-R, Yoshida S, Naito K, Kurihara H, Ueno M,
et al. Characterization and Stabilization of a New 64Cu-Labeled Anti-EGFR Antibody NCAB001 for the Early Detection of Pancreatic Cancer with Positron Emission Tomography. Pharmaceutics. 2022; 14(1):67.
https://doi.org/10.3390/pharmaceutics14010067
Chicago/Turabian Style
Matsumoto, Hiroki, Chika Igarashi, Tomoko Tachibana, Fukiko Hihara, Atsuo Waki, Ming-Rong Zhang, Sei Yoshida, Kenichiro Naito, Hiroaki Kurihara, Makoto Ueno,
and et al. 2022. "Characterization and Stabilization of a New 64Cu-Labeled Anti-EGFR Antibody NCAB001 for the Early Detection of Pancreatic Cancer with Positron Emission Tomography" Pharmaceutics 14, no. 1: 67.
https://doi.org/10.3390/pharmaceutics14010067
APA Style
Matsumoto, H., Igarashi, C., Tachibana, T., Hihara, F., Waki, A., Zhang, M.-R., Yoshida, S., Naito, K., Kurihara, H., Ueno, M., Ito, K., Higashi, T., & Yoshii, Y.
(2022). Characterization and Stabilization of a New 64Cu-Labeled Anti-EGFR Antibody NCAB001 for the Early Detection of Pancreatic Cancer with Positron Emission Tomography. Pharmaceutics, 14(1), 67.
https://doi.org/10.3390/pharmaceutics14010067
